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AIMS
The assessment of heart rate-corrected QT (QTc) interval prolongation
relies on the evidence of drug effects in healthy subjects. This study
demonstrates the relevance of pharmacokinetic–pharmacodynamic
(PKPD) relationships to characterize drug-induced QTc interval
prolongation and explore the discrepancies between clinical trials and
real-life conditions.
METHODS
d,l-Sotalol data from healthy subjects and from the Rotterdam Study
cohort were used to assess treatment response in a phase I setting and
in a real-life conditions, respectively. Using modelling and simulation,
drug effects at therapeutic doses were predicted in both populations.
RESULTS
Inclusion criteria were shown to restrict the representativeness of the
trial population in comparison to real-life conditions. A significant part
of the typical patient population was excluded from trials due to
weight and baseline QTc interval criteria. Relative risk was significantly
different between sotalol users with and without heart failure,
hypertension, diabetes and myocardial infarction (P < 0.01). Although
drug effects do cause an increase in the relative risk of QTc interval
prolongation, the presence of diabetes represented an increase from
4.0 [95% confidence interval (CI) 2.7–5.8] to 6.5 (95% CI 1.6–27.1), whilst
for myocardial infarction it increased from 3.4 (95% CI 2.3–5.13) to 15.5
(95% CI 4.9–49.3).
CONCLUSIONS
Our findings show that drug effects on QTc interval do not explain the
observed QTc values in the population. The prevalence of high QTc
values in the real-life population can be assigned to co-morbidities and
concomitant medications. These findings substantiate the need to
account for these factors when evaluating the cardiovascular risk of
medicinal products.
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Safety signals regarding drug effects on cardiac
conductivity have been found after the approval of
medicines, despite evidence suggesting that they could be
deemed safe during development.
• Such a discrepancy may be caused by the known
differences between real-life conditions and clinical trial
protocols, which represent a subset of the patient
population, as defined by the many inclusion and exclusion
criteria. No formal quantitative method is available to assess
the clinical implications of such differences.
• Modelling and simulation have been successfully applied as
a tool for evidence synthesis in drug development. In
conjunction with Bayesian statistics, modelling and
simulation allow inferences to be made about the response
to treatment, taking into account drug- and disease-specific
properties as well as population characteristics.
WHAT THIS STUDY ADDS
• The concept of not-in-trial simulations is introduced as a
tool for risk management, integrating
pharmacokinetic–pharmacodynamic relationships as the
basis for discriminating drug-specific properties from other
relevant factors in noncontrolled settings.
• Using d,l-sotalol as an example compound, we show that a
model-based approach can be used to evaluate heart
rate-corrected QT (QTc) interval prolongation in clinical
trials and predict drug-induced effects in real-life
conditions.
• In addition, our results clearly indicate that the effect of
concomitant medications and co-morbidities needs to be
considered in parallel when assessing the propensity for
the prolongation of QTc interval.
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Introduction
In the last two decades, there have been increased con-
cerns around the rising number of pro-arrhythmia cases
due to non-antiarrhythmic drug-induced QTc prolonga-
tion [1]. Physiologically, the duration of the QT interval on
the surface electrocardiogram (ECG) represents the ven-
tricular action potential duration. As such, prolonged heart
rate-corrected QT (QTc) interval may result in early after-
depolarizations, which may induce re-entry and provoke
Torsade de Pointes [2, 3]. Even though epidemiological evi-
dence regarding the correlation between drug-induced
QTc interval prolongation and the risk of fatal arrhythmias
remains under scrutiny [4, 5], QTc prolongation has
become the second most common cause for postmarket
drug withdrawal [6, 7].
Given that in most cases the pro-arrhythmic effects
were unclear or unobserved during clinical development,
regulatory bodies started to monitor closely the liability for
QTc interval prolongation in the submissions of new
chemical entities. Guidelines have also emerged outlining
the prerequisites for the evaluation of drug-induced
effects on heart conductivity and QTc interval during
development [8, 9]. More recently, a thorough QT (TQT)
study has been defined as a requirement for the clinical
evaluation of the pro-arrhythmic potential of non-
antiarrhythmic drugs [10].
From a methodological perspective, the TQT protocol
design relies on the use of a positive control as well as
supratherapeutic doses of the investigational drug to
assess QT/QTc interval prolongation. Whilst the sensitivity
of the proposed data analysis methods has been the
subject of debate in numerous publications, less attention
has been paid to the implications of overlooking the
underlying concentration–QTc effect relationship and con-
sequently to the availability of supporting evidence for
extrapolation of the findings to real-life conditions [11, 12].
Taking into account PKPD relationships, we explore the
implications of the known differences between clinical trial
populations and real-life conditions, with special focus on
the potential impact of protocol inclusion and exclusion
criteria. Although it may be understandable and desirable
to characterize the safety profile of a drug in healthy sub-
jects, we show how inclusion/exclusion criteria lead to a
somewhat biased estimation of the drug effects in the
patient population who will receive the treatment after
approval. In particular, the exclusion of severely ill sub-
groups or those with higher risk factors for Torsade de
Pointes is usually not factored in a quantitative manner
when evaluating clinical trial results. These subgroups
include females, elderly subjects, those with predisposed
cardiac or noncardiac diseases associated with diminished
repolarization reserve, those with pharmacogenetic
defects of drug-metabolising enzymes or pharmacological
targets such as the potassium channels, those susceptible
to bradycardia or electrolyte imbalance, or those receiving
drugs with a potential for pharmacokinetic or pharmacody-
namic interactions [13,14].In addition,little importance has
been ascribed to the role of other factors contributing to
QTc interval prolongation in the patient population,in com-
parison to the observed drug effect in healthy subjects [12,
15]. Consequently, no formal procedures exist to mitigate
the impact of such differences or support the management
of cardiovascular risk in the target population.
In fact, from a clinical standpoint one should raise ques-
tions about the reliability of the inferences made from
pre-approval clinical trials. Given the patient population
enrolled, the background noise and the relatively low fre-
quency of clinically relevant arrhythmogenic effects, the
signal arising from clinical trials may or may not accurately
detect the rate and extent of QTc interval prolongation [1].
Therefore, sponsors, regulatory agencies and other stake-
holders need to consider how best to predict the pro-
arrhythmic liability of a medicinal product, taking into
account the contribution of other factors in the target
population in real-life conditions.
Using d,l-sotalol as an example compound, the primary
objective of this investigation is to characterize the differ-
ences in QTc interval following administration of therapeu-
tic doses of this compound to healthy subjects in clinical
trials and to patients in real life. Based on imputation
procedures, we subsequently use the predicted
concentration–effect relationship to identify the effect of
other influential covariates contributing to QTc interval
prolongation in patients. Our approach relies on hierarchi-
cal modelling and simulation principles as a tool for evi-
dence synthesis in the evaluation of drug safety [16, 17]. In
contrast to previous applications of modelling and simula-
tion [18–20], we show how simulations can be used to
explore the role of design factors that have been omitted
or excluded from a randomized trial. Thus, we anticipate
that our approach will represent a natural extension of
ongoing efforts within the pharmaceutical industry to
improve safety signal detection [21–25].
Methods
Real-life study population
The real-life population setting was derived from the Rot-
terdam Study.The study is a prospective population-based
cohort study, which started with a baseline visit between
1990 and 1993. All inhabitants of a suburb in Rotterdam,
Ommoord, aged 55 years and over were invited to partici-
pate. Of the 10 275 subjects invited, 7983 (78%) gave their
written informed consent and took part in the baseline
examination. The study was approved by the Medical
Ethics Committee of the Erasmus Medical Center, Rotter-
dam, The Netherlands. Objectives and methods of investi-
gation have been described in detail in other publications
[26]. All participants were visited at home for a standard-
ized questionnaire, and 7151 were subsequently examined
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at the research centre. A second, third and fourth follow-up
visit took place, respectively,during 1993–1995,1997–1999
and 2002–2004. In addition to follow-up examinations, the
cohort is continuously monitored for major morbidity and
mortality through linkage with general practitioner and
municipality records. Drug prescriptions dispensed to par-
ticipants by automated pharmacies have been routinely
stored in the database since 1 January 1991. For the
present study, we included all participants in the Rotter-
dam Study with at least two consecutive ECG assessments.
All subjects who started treatment with d,l-sotalol
during follow-up were included in the present study, with
the exception of prevalent users and subjects with left ven-
tricular hypertrophy, right bundle-branch block and left
bundle-branch block, who were excluded. The reason for
the exclusion of these patients is that left ventricular
hypertrophy, right bundle-branch block and left bundle-
branch block can cause secondary repolarization changes
and atrial fibrillation can cause difficulties in measuring QT
intervals. From the remaining population, ‘new’ sotalol
users were identified as those receiving their first prescrip-
tion after enrolment into the study. Our analysis included
all QTc measurements after the start of sotalol treatment
for all new users.
During the research centre visit, nonfasting blood
samples were obtained [27]. Body mass index was com-
puted as weight divided by height squared. Co-morbidities
were screened and identified according to standard
clinical criteria. Hypertension was defined as systolic
blood pressure >160 mmHg or diastolic blood pressure
>100 mmHg and/or use of antihypertensive medications,
encompassing grade 2 and grade 3 hypertension com-
pounds, according to the World Health Organization crite-
ria [28]. Diabetes mellitus was defined as the use of blood
glucose-lowering medication and/or a nonfasting or post-
load serum glucose level of 11.1 nmol l-1 or higher, accord-
ing to the World Health Organization [29]. A history of
myocardial infarction was assessed by self-report checked
with records from the general practitioner or cardiologist
and/or electrocardiographic evidence. All reported myo-
cardial infarctions were verified against the medical
records as described in detail previously [30]. Assessment
of heart failure at baseline and during follow-up was
assessed by reviewing all medical records for the occur-
rence of at least two signs and symptoms suggestive of
the disease or the use of medication for heart failure and
hospital discharge letters. Cases of incident heart failure
were obtained by continuously monitoring the partici-
pants [31, 32]. The ankle brachial pressure index was used
as potential predictor of cardiovascular diseases and mor-
tality [33].
Healthy subject population
A study on healthy subjects using d,l-sotalol was selected
from GlaxoSmithKline’s clinical data repository (study
number EXP20001). The primary objective of this study
was to assess the role of intrinsic and extrinsic factors on
the variability of QTc interval and was powered to detect a
10 ms increase in QTc.The study had a placebo-controlled,
three-way crossover design, with two placebo periods and
one active treatment period. Blood concentrations were
taken at -30, 5, 15, 30 and 45 min relative to dosing time, as
well as 1, 2, 4, 8, 10, 18 and 24 h after the dose. The study
population comprised 30 subjects (12 females and 18
males) between the ages of 19 and 47 years.
Relevant eligibility criteria for inclusion into [items (i)–
(iii)] and exclusion from [items (iv)–(viii)] the study for the
purposes of our investigation were as follows: (i) age
between 18 and 55 years, inclusive; (ii) nonsmoker (subject
must have been a nonsmoker for at least 3 months prior
to screening); (iii) body mass index between 19 and
30 kg m-2, with a weight of 50–95 kg, inclusive; (iv) at
screening, ECG recording showed abnormal QRST complex
morphology, sinus bradycardia (heart rate <45 beats min-1,
PR interval >210 ms) or QTc interval values above 420 or
440 ms for males and females, respectively; (v) any medical
history which was contra-indicated in the SOTACORTM
product label; (vi) history of hypertension, asthma, bron-
chial hyperactivity or peripheral vascular disease, including
diabetes; (vii) the subject had a history of alcohol or drug
abuse; and (viii) the subject was positive for HIV, hepatitis C
or hepatitis B surface antigen.
Drug-induced QTc interval prolongation
The simulation of QTc intervals was performed according
to a two-step approach. First, drug concentrations in the
target population (i.e. sotalol users) were derived using a
pharmacokinetic model. The QTc intervals were subse-
quently obtained using final population pharmacokinetic–
pharmacodynamic (PKPD) parameter estimates.
The pharmacokinetics of d,l-sotalol was described by a
two-compartment, first-order absorption pharmacokinetic
model, with weight as a covariate on clearance, using
nonlinear mixed-effects modelling, as implemented in
NONMEM (v5.1; ICON Development Solutions, Ellicott City,
MD, USA) [34]. Heart rate-corrected QT intervals were
described by a PKPD model, in which physiological (QT and
RR) and drug-specific (concentration) parameters are
parameterized in an independent manner (equation 1)
[35]. A detailed description of the model development was
described in a previous publication [11].
QTc QT RR slope= × + −( ) + ×0 224α π ϕA t Ccos ( )
(equation 1)
where QT0 (in milliseconds) is the intercept of the QT–RR
relationship (sex was included as a covariate for this
parameter whenever applicable, RR (in milliseconds) is the
interval between successive R waves, a is the individual
heart rate correction factor,A (in milliseconds) is the ampli-
tude of the circadian rhythm, t is the clock time, j is the
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phase, slope (in milliseconds per nanogram per millilitre) is
the linear pharmacodynamic relationship, and C is the pre-
dicted concentration of drug at the time of QT interval
measurements. It should be noted that we have chosen to
express the QTc interval in milliseconds, as accepted in
clinical practice. However, dimensional analysis of the
formula, taking into account the heart rate variation,
shows that the proper dimensions of QTc should be
(milliseconds)1/2, not milliseconds. Ambiguities involving
formulae in terms of heart rate are eliminated by express-
ing them in terms of RR. When viewed from the physical
rather than the statistical perspective, the formulae for QT
as a function of RR are equivalent to the duration of the
systole as a function of heart rate [36].
The effect of drug-induced QTc prolongation in the
Rotterdam Study population was then simulated using the
PKPD model, taking into account the demographic and
clinical characteristics of the patients in this cohort. Popu-
lation mean estimates were used for the simulations (slope
= 0.02 ms ng-1 ml-1 and intercept (QT0) = 380 ms), with the
exception of the drug concentrations, which were simu-
lated using the individual body weight of the patients. Full
compliance to treatment was assumed for the purposes of
our analysis. Finally, QTc values in the Rotterdam Study
population were compared nonparametrically with the
observed data.
Electrocardiographic measurements
For the Rotterdam Study cohort, a 10 s 12-lead ECG, result-
ing on average in 8–10 heart beats, was recorded with an
ACTA electrocardiograph (ESAOTE, Florence, Italy) at a sam-
pling frequency of 500 Hz and stored digitally. All ECGs
were processed by the Modular ECG Analysis System
(MEANS) to obtain the ECG parameters of interest. The
MEANS program has been evaluated extensively [37, 38].
MEANS determines common onset and offset for all 12
leads together for one representative averaged beat, with
the use of template matching techniques, until the end of
the T wave. To adjust for heart rate, Bazett’s formula (QTc =
QT/RR1/2) was used [39]. A total of 1387 digitally stored ECG
records were used for this study.
In contrast, ECG measurements in healthy volunteers
were recorded in triplicate and read manually from lead II
by a blinded cardiographer. The average value from the
triplicates was used for data analysis and development of
the PKPD model.
Comparison between controlled trials and
real-life conditions
After applying the target population selection criteria to
the Rotterdam Study, 608 subjects were classified as ‘new’
sotalol users without left ventricular hypertrophy, right
bundle-branch block or left bundle-branch block.The total
accumulated follow-up was 4864 years (i.e. a mean SD of
8 1.5 years per subject),during which they all had at least
one ECG measurement. At the end, there were a total of
1375 available ECGs, with an average of two per person.
Inclusion and exclusion criteria from the phase I sotalol
trial were then applied to this subset to allow further char-
acterization of the differences between the real-life condi-
tions and the clinical trial protocol.
Statistical analysis
Observed and expected QTc intervals were nonparametri-
cally compared visually and statistically, by determining
the significance of the differences between the two distri-
butions. Specifically, the Wilcoxon signed-rank test was
used to evaluate whether the distributions differed signifi-
cantly from each other, with a P value < 0.05.
The effect of influential covariates was assessed by the
changes in relative risk. The relative risk together with the
95% confidence interval of the association between ‘pro-
longed’ QTc, defined as >450 ms for males and >470 ms for
females, and concomitant use of medications and pres-
ence of co-morbidities while on sotalol prescription were
estimated using a Cox’s proportional hazards analysis [40].
At each ECG measurement, all information concerning
medications and co-morbidities was updated. Repeated
measurements in a given subject were treated independ-
ently, because within-subject variability could not be con-
sidered in this analysis.
Results
The use of inclusion and exclusion criteria from the phase I
trial for the subset of patients selected from the Rotterdam
Study revealed important differences between clinical trial
protocols and real-life conditions. Figure 1 shows that
10.8% of the male population and 3.4% of the female
population from the Rotterdam Study would have been
excluded based on their body weight. Likewise, 21.9% of
male and 14.9% of female subjects would not be included
due to their baseline QT interval measurements (Figure 2).
Pharmacokinetic and PKPD model parameters were
used to test whether drug effects alone could explain the
observed QTc values in the observational real-life cohort.
The simulated QTc intervals (i.e. the expected drug-
induced QTc interval prolongation) were found to differ
from the observed values (Figure 3), especially in the male
population.Using the Wilcoxon signed-rank test, our analy-
sis shows that the two distributions were significantly dif-
ferent from each other in both genders (P < 0.05). The
distribution of observed QTc values in sotalol users in the
elderly population revealed some dangerously high meas-
urements. These observations contrast with model-based
predictions, suggesting that drug-induced effects alone
cannot describe the observed QTc interval.
Further evaluation of the differences between the two
populations was performed by binary logistic regression,
which revealed the contribution of concomitant medica-
tions and co-morbidities as QTc-prolonging factors
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(Table 1). As expected, a 4.0-fold increase in relative risk
for QTc interval prolongation was found in sotalol users,
in comparison to nonsotalol users. In contrast, it was
also clear that in the absence of any drug treatment,
co-morbidities caused a significant increase in the relative
risk for QTc interval prolongation (Table 1), which ranged
in ascending order from 3.4 to 7.4 times for myocardial
infarction, diabetes, heart failure and hypertension. The
prescription of sotalol modifies the underlying relative
risks. A reduction in the impact caused by the co-
morbidities was observed for heart failure and hyperten-
sion, whilst a further increase was seen for diabetes
(1.62 times higher) and myocardial infarction (3.87 times
higher). The magnitude of the interaction between treat-
ment and co-morbidities cannot be explained by differ-
ences in the pharmacokinetics or pharmacodynamics of
sotalol.
Discussion
Our results show that the population selection and
inclusion/exclusion criteria applied to clinical protocols in
early drug development may lead to significant differences
between drug-induced and overall treatment effect size in
the target population. Thus far, the evidence of pro-
arrhythmic effects in real-life patients has been primarily
assigned to the pharmacological treatment, i.e. to drug
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effects. The present investigation strongly suggests that
the signal detected during a TQT study does not accurately
predict the interaction between drug effects and other
disease-related factors, which together may lead to further
increase in the cardiovascular risk associated with the
arrhythmogenic effects of a drug.
The use of a model-based approach enables us to
make inferences about drug exposure in patients and
to evaluate, in an integrated manner, how different
covariates and other sources of variability affect the
observed QTc values in real-life patients. Our results
indicate that other causal factors are present, which
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Table 1
Results of the relative risk calculations for prolonged QTc interval, as defined in epidemiological cohorts
Co-morbidity and
corresponding co-medications
Relative risk (95% confidence
interval) in sotalol nonusers P value
Relative risk (95% confidence
interval) in sotalol users P value
Using sotalol alone – <0.01 4.0 (2.7–5.8) <0.01
Diabetes 4.0 (2.7–5.8) <0.01 6.5 (1.6–27.1) <0.01
Heart failure 4.4 (3.0–6.6) <0.01 0.8 (0.2–3.4) <0.01
Hypertension 7.4 (4.3–12.7) <0.01 2.4 (1.3–4.2) <0.01
Myocardial infarction 3.4 (2.3–5.127) <0.01 15.5 (4.9–49.3) <0.01
The effect of sotalol alone, i.e. drug-specific effect, is shown on the first row. Significance level was set at P < 0.05.
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significantly affect the observed QTc values in uncon-
trolled, real-life conditions. In fact, our findings are in
agreement with previous publications, which show that
heart failure, hypertension, diabetes and myocardial inf-
arction increase the risk of QTc prolongation [41–44].
However, the absolute changes in relative risk associated
with co-morbidities varied considerably when considered
together with the use of sotalol. A clear reduction in the
relative risk was observed for hypertension and heart
failure, with further increases for diabetes and myocardial
infarction. Given that patients were also being prescribed
treatment for these co-morbidities, a distinction between
the effect of disease and other drugs is not possible. Fur-
thermore, in this specific case, no evidence exists to
support that the prescribed co-medications could lead
to potential pharmacokinetic and/or pharmacodynamic
interactions with sotalol.
The concepts outlined in the present investigation
also show how clinical trial and epidemiological data can
be used in an integrated manner for the purpose of
signal detection and improved risk management. Our
findings appear to confirm the points highlighted by
Black on ‘the false conflict between those who advocate
randomized trials in all situations and those who believe
observational data provide sufficient evidence needs to
be replaced with mutual recognition of the complemen-
tary roles of the two approaches’ [45]. Others have also
advocated the synergistic potential for using both kinds
of data to aid decision making [46–49]. In the design
of this study, we applied a parametric approach, in which
simulations played a central role. As a matter of fact,
this is the first time that simulations based on nonlinear
hierarchical models have been used to characterize the
implications of exclusion criteria on the overall safety
profile.
By applying PKPD modelling concepts to epidemio-
logical data, we have also shown that the PKPD relation-
ships derived from healthy volunteers do not necessarily
describe or predict what will happen in real-life conditions.
New approaches are required to assess the impact of QTc
prolongation, taking into account not only the drug
effects. This prerequisite clearly challenges the validity of
the TQT study as the state-of-the-art approach for deter-
mining the risk of pro-arrhythmia or Torsade de Pointes. In
this context, an important advantage of the use of PKPD
relationships is that even if pharmacokinetics has been
evaluated at supratherapeutic levels, drug exposure can be
extrapolated to reflect drug concentrations observed after
therapeutic doses, so that accurate inferences and recom-
mendations can be made about the potential drug effects
on QTc interval.
Indirectly, our results highlight the importance of
assessing the clinical implications of adverse drug effects
in vulnerable or high-risk population subgroups (e.g.drug–
drug interactions) in a more quantitative manner. We
therefore anticipate the use of our approach to assess
treatment effects in these subgroups by introducing such
patients into simulation scenarios.
Despite the potential impact of a tool for not-in-trial
simulations, the proposed approach in this investigation
has some limitations. First, it should be noted that popu-
lation estimated parameters rather than the individual
estimates were used in the simulations. This reduces the
overall interindividual variability that exists within a
population. In addition, an assumption was made that all
the subjects in the Rotterdam Study were fully compliant
with medication consumption so that the same plasma
concentration range was reached as in the subjects in the
clinical trial. Differences in the procedures, timing and
equipment used for ECG monitoring in the Rotterdam
Study and in the clinical trial were assumed to contribute
to increased random variation without introducing sig-
nificant bias. The implications of the aforementioned
assumptions cannot be fully evaluated with the existing
data. An external validation approach is desirable and
required to dismiss potential biases and confounders. We
have therefore initiated a follow-up research protocol, in
which the same approach is applied to another cohort,
including different study drugs.
In summary, the concept of not-in-trial simulations has
been introduced as a tool for the evaluation of QTc interval
prolongation in real-life conditions, integrating PKPD rela-
tionships as the basis for differentiating drug-specific
properties from other relevant factors in noncontrolled
settings. Moreover, we have shown that co-morbidities can
have a significant contribution to the observed QT prolon-
gation in the overall population.The impact of such factors
cannot be derived empirically from a TQT study in healthy
subjects.
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